Biotech entity

Statistics Korea

organization

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Plug Power, the most common co-covered peer. The tracked stories average 4 original sources each. Statistics Korea appears in 1 tracked Biotech story from March 4, 2026.

Last mentioned: Mar 5, 2026

Entity pulse

Recent coverage · Statistics Korea

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Statistics Korea

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Plug Power, the most common co-covered peer. The tracked stories average 4 original sources each. Statistics Korea appears in 1 tracked Biotech story from March 4, 2026.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Statistics Korea. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. STAAR Surgical Q4 Results

    STAAR Surgical announces narrowed Q4 losses, beating some analyst expectations for fiscal discipline.

  2. South Korea Economic Data

    Statistics Korea reports a 1.7% decline in industrial output for January 2026.

  3. Indian Market Holiday

    Markets in India remain closed in observance of the Holi festival.

  4. Plug Power Earnings

    Hydrogen energy leader Plug Power reports a narrowed loss per share for the fourth quarter.

Stories mentioning Statistics Korea 1

Pharma Neutral

STAAR Surgical Narrows Q4 Loss Amid Ophthalmic Market Resilience

STAAR Surgical reported a narrowed net loss for the fourth quarter, signaling operational efficiency and steady demand for its EVO ICL lens technology. The results highlight the company's resilience in the premium refractive surgery market despite broader macroeconomic headwinds in key Asian markets.

4 sources

Statistics Korea is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.